Estramustine
| Clinical data | |
|---|---|
| Trade names | Emcyt, Estracyt |
| Other names | EM; EaM; Leo 275; Ro 21-8837; Estradiol 3-(bis(2-chloroethyl)carbamate) ester; Estra-1,3,5(10)-triene-3,17β-diol 3-(bis(2-chloroethyl)carbamate) ester |
| Drug class | Chemotherapeutic agent; Estrogen; Estrogen ester |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.019.161 |
| Chemical and physical data | |
| Formula | C23H31Cl2NO3 |
| Molar mass | 440.41 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Estramustine (INN, USAN, BAN) is an estrogen and cytostatic antineoplastic agent which was never marketed. It is a carbamate derivative of estradiol and acts in part as a prodrug of estradiol in the body. Estramustine phosphate, the C17β phosphate ester of estramustine and a prodrug of estramustine, estromustine, estradiol, and estrone, is marketed and used in the treatment of prostate cancer.